Nasus Pharma is trading at $3.50, down 7.28%, during the October 8 session amid broad risk-off pressure, as higher oil prices and Treasury yields stoked inflation worries and weighed on U.S. stocks.
- Healthcare was also down, adding sector pressure.
- Searches found no clear company-specific catalyst. The annual shareholder meeting was scheduled for October 8, but no evidence links it to the decline.
- Trading volume information was unavailable in the provided price context.